Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Third Harmonic Bio, Inc. (THRD : NSDQ)

• Company Description    Third Harmonic Bio Inc. is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation. The company's principal candidate includes THB001, is a highly selective, oral small-molecule inhibitor of KIT. Third Harmonic Bio Inc. is based in CAMBRIDGE, Mass. Number of Employees: 53

• Price / Volume Information    Yesterday's Closing Price: $5.45 Daily Weekly Monthly 20 Day Moving Average: 189,155 shares Shares Outstanding: 45.13 (millions) Market Capitalization: $245.95 (millions) Beta: 2.12 52 Week High: $16.02 52 Week Low: $3.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.74% -3.03% 12 Week 5.62% -11.16% Year To Date -47.04% -50.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1700 MONTGOMERY STREET SUITE 210 - SAN FRANCISCO,CA 94111 USA ph: 209-727-2457 fax: - investors@thirdharmonicbio.com http://www.thirdharmonicbio.com

• General Corporate Information    Officers Natalie Holles - Chief Executive Officer and Director Christopher M. Murphy - Chief Financial and Business Officer and Mark Iwicki - Director David P. Bonita - Director Michael Gladstone - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 88427A107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 45.13 Most Recent Split Date: (:1) Beta: 2.12 Market Capitalization: $245.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -75.00% vs. Previous Quarter: -20.69% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -19.27 12/31/24 - -16.53 ROA 06/30/25 - - 03/31/25 - -18.67 12/31/24 - -16.02 Current Ratio 06/30/25 - - 03/31/25 - 54.10 12/31/24 - 40.87 Quick Ratio 06/30/25 - - 03/31/25 - 54.10 12/31/24 - 40.87 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 6.04 12/31/24 - 6.33 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©